Comparing Dexamethasone and Prednisolone in Treating Low Platelet Counts in Children with Immune Thrombocytopenic Purpura: A Single-Center Study
Not Applicable
- Conditions
- Health Condition 1: D693- Immune thrombocytopenic purpura
- Registration Number
- CTRI/2024/05/067294
- Lead Sponsor
- All India Institute of Medical Sciences, Patna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of ITP visiting OPD/admitted in Paediatrics ward of AIIMS Patna who are between 1 to 18 years of age and have not received steroids in past 1 month and require treatment as per the protocol
Exclusion Criteria
1. Patients with inherited platelet disorders (Bernard-Soulier syndrome, Glanzmann thrombasthenia, etc.)
2. Patients with known rheumatological diseases already on steroids or steroid sparing drugs (SLE, APLA, etc.)
3. Patients with known malignancy receiving chemotherapy and/or radiotherapy.
4. Patients of aplastic anemia
5. Patients of chronic or persistent ITP
6. Patients taking antiplatelet drugs.
7. Patients who received steroid(s) or IVIG or platelet transfusion(s) prior to presenting to AIIMS Patna.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement or resolution of thrombocytopeniaTimepoint: At baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7, 1 month and 6 months
- Secondary Outcome Measures
Name Time Method a.To assess the likelihood of progression to persistent ITP in children treated with dexamethasone as compared to that with of prednisolone.Timepoint: 6 months;b.Time spent under the danger zone of risk of bleeding i.e., platelet count less than 20,000/mm3 during treatment with either agentTimepoint: 6 months;To assess the need for platelet transfusion in both categoriesTimepoint: 6 months;To compare the steroid toxicity/adverse effects in both categoriesTimepoint: 6 months